Details of the Drug

General Information of Drug (ID: DMFIP0D)

• Drug Name: Imidazo[1,5-a]pyridine derivative 1
• Synonyms: PMID29473428-Compound-12
• Drug Type: Small molecular drug
• #Ro5 Violations (Lipinski): 0:
  Molecular Weight (mw); 264.75
  Logarithm of the Partition Coefficient (xlogp); 4
  Rotatable Bond Count (rotbonds); 2
  Hydrogen Bond Donor Count (hbonddonor); 1
  Hydrogen Bond Acceptor Count (hbondacc); 2
• Chemical Identifiers:
  Formula: C14H17ClN2O
  IUPAC Name: (S)-(7-chloroimidazo[1,5-a]pyridin-5-yl)-cyclohexylmethanol
  Canonical SMILES: C1CCC(CC1)[C@@H](C2=CC(=CC3=CN=CN23)Cl)O
  InChI: InChI=1S/C14H17ClN2O/c15-11-6-12-8-16-9-17(12)13(7-11)14(18)10-4-2-1-3-5-10/h6-10,14,18H,1-5H2/t14-/m0/s1
  InChIKey: AVJCRIIDMDBAQC-AWEZNQCLSA-N
• Cross-matching ID:
  PubChem CID: 122604981
  ChEBI ID: CHEMBL5203175
  TTD ID: D0ZV6F
• Drug-Molecule Activity Atlas (DMA)NEW: Click to Jump to the Detailed DMA Information of This Drug

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Indoleamine 2,3-dioxygenase 1 (IDO1)	TTZJYKH	I23O1_HUMAN	Inhibitor	[1]

References

• [1] A patent review of IDO1 inhibitors for cancer.Expert Opin Ther Pat. 2018 Apr;28(4):317-330.